Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: By reducing injections from 365 to 52 per year at near price parity, and potentially 20–25% lower annual treatment costs versus some analogue basals,&nbs...
